抗血栓形成药物的研究进展

doi:10.16352/j.issn.1001-6325.2023.01.0183

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (1): 183-187.doi: 10.16352/j.issn.1001-6325.2023.01.0183

抗血栓形成药物的研究进展

张杰^1,2, 麻旭州^1,2, 李慧慧^1,2, 王淼^1,2*

1.浙江师范大学化学与生命科学学院,浙江金华 321000;
2.中国医学科学院北京协和医学院国家心血管病中心阜外医院心血管疾病国家重点实验室, 北京 100037

收稿日期:2021-09-13 修回日期:2022-02-08 发布日期:2022-12-27
通讯作者: ^*wangmiao_frank@aliyun.com
基金资助:
国家重点研发计划(2020YFC2008000);中国医学科学院医学与健康技术创新工程(2017-I2M-1-008,2016-I2M-1-003)

Research progress of antithrombotic drugs

ZHANG Jie^1,2, MA Xuzhou^1,2, LI Huihui^1,2, WANG Miao^1,2*

1. College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321000;
2. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS & PUMC, Beijing 100037, China

Received:2021-09-13 Revised:2022-02-08 Published:2022-12-27
Contact: ^*wangmiao_frank@aliyun.com

摘要/Abstract

摘要： 血栓形成是动脉粥样硬化性心血管疾病患者急性表征(心肌梗死,卒中)的主要直接诱因。在全球范围内,血栓栓塞性疾病的发病率近年来有所增加,患者病死率也随之增加。目前,针对血栓栓塞性疾病,已经发展了几种靶向给药策略,其中包括抗血小板药物和抗凝血药物,随着抗血栓形成药物的研究进展,治疗血栓导致的心血管疾病为患者带来了巨大的潜在效益。

关键词: 血栓, 药物, 抗血小板, 抗凝血

Abstract: Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient mortality. Currently,several targeted drug delivery strategies have been developed for thromboembolic diseases, including antiplatelet drugs and anticoagulant drugs. With the development of antithrombotic drugs, the treatment of cardiovascular diseases caused by thrombus shows significant potential benefit for patients.

Key words: thrombus, drugs, antiplatelet, anticoagulant

中图分类号:

R364.1+5

张杰, 麻旭州, 李慧慧, 王淼. 抗血栓形成药物的研究进展[J]. 基础医学与临床, 2023, 43(1): 183-187.

ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao. Research progress of antithrombotic drugs[J]. Basic & Clinical Medicine, 2023, 43(1): 183-187.

参考文献

[1] Mackman N, Bergmeier W, Stouffer GA,et al. Thera-peutic strategies for thrombosis: new targets and appro-aches[J]. Nat Rev Drug Discov, 2020,19: 333-352.
[2] 《中国心血管疾病与报告2020》编写组.《中国心血管疾病与健康》要点解读[J]. 中国心血管杂志, 2021, 26: 209-218.
[3] Roth GA,Mensah GA,Johnson CO.et al.Global burden of cardiovascular diseases and risk factors, 1990—2019: update from the GBD 2019 Study[J].J Am Coll Cardiol, 2020, 76: 2982-3021.
[4] Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture[J]. J Intern Med, 2014, 276: 618-632.
[5] Thompson AE. Deep vein thrombosis[J]. JAMA, 2015, 313: 2090-2090.
[6] Baqi Y,Muller CE.Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery[J]. Drug Discov Today,2019, 24:325-333
[7] Zwart B, Parker WAE, Storey RF. New antithrombotic drugs in acute coronary syndrome[J]. J Clin Med, 2020, 9: 2059-2077.
[8] Capodanno D, Angiolillo DJ.Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus[J]. Circulation,2020, 142:2172-2188.
[9] Patrono CM, Baigent C, Collet J,et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis[J]. JAmCollCardiol, 2017, 70: 1760-1776.
[10] Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy[J]. Am J Med, 2016, 129: 1198-1204.
[11] Warkentin TE, Pai M, and Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review[J]. Blood, 2017, 130: 1104-1113.
[12] Schüpke S,Hein-Rothweiler S,Mayer K, et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective pci-design and rationale of the randomized isar-plaster trial[J]. Thromb Haemost, 2019, 119: 1539-1545.
[13] Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergo-ing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled isar-plaster phase 2 trial[J]. JAMA Cardiol, 2021, 6: 753-761.
[14] Mackman N, Bergmeier W, Stouffer GA, et al.Therapeu-tic strategies for thrombosis: new targets and approaches[J]. Nat Rev Drug Discov 2020, 19: 333-352.
[15] Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events[J]. N Engl J Med, 2012, 366: 1404-1413.
[16] Suehiro E, Fujiyama Y, Kiyohira M, et al. Risk of deterioration of geriatric traumatic brain injury in patients treated with antithrombotic drugs[J].World Neurosurg,2019, 127:e1221-e1227.
[17] Weitz JI,Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism[J]. Blood, 2020, 135: 351-359.
[18] Lorentz CU, Verbout NG, Wallisch M,et al.Contact activation inhibitor and factor Ⅺ antibody, ab023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial[J]. Arterioscler Thromb Vasc Biol, 2019, 39: 799-809.
[19] Koch AW, Schiering N, Melkko S, et al.MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans[J]. Blood, 2019, 133: 1507-1516.
[20] Pireaux V, Tassignon J, Demoulin S, et al. Anticoagula-tion with an inhibitor of factors Ⅺa and Ⅻa during cardiopulmonary bypass[J]. J Am Coll Cardiol, 2019, 74: 2178-2189.
[21] Bauml M, Hilgendorf I. Future antithrombotic therapies in cardiology[J]. Hamostaseologie, 2018, 38: 236-239.
[22] Bielecki S, Lee D,Hamad B. The market for oral anticoagulants[J]. Nat Rev Drug Discov, 2018, 17: 617-618.

抗血栓形成药物的研究进展

Research progress of antithrombotic drugs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	沙务嘎, 李隽. 高通量筛选NMNAT1抑制剂及其肿瘤杀伤作用[J]. 基础医学与临床, 2022, 42(6): 933-939.
[2]	左宇志, 严维刚. 抗血栓药物的应用与前列腺穿刺活检术的安全性[J]. 基础医学与临床, 2022, 42(5): 824-827.
[3]	赵川榕, 周菁. 靶向剪切力敏感关键分子的动脉粥样硬化防治研究[J]. 基础医学与临床, 2022, 42(3): 378-383.
[4]	刘畅, 郭向阳. 局部麻醉药物在肿瘤转移和复发中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 512-515.
[5]	刘辰, 方思尹, 顾操, 吴晋晖. 抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展[J]. 基础医学与临床, 2022, 42(2): 325-329.
[6]	邹兴龙, 陈柱先, 孙娟娟, 蔡江滢, 苏露, 马薇, 傅思武. 壳聚糖药用制剂及其应用的研究进展[J]. 基础医学与临床, 2022, 42(11): 1791-1794.
[7]	曹意, 蒋晨. 脑靶向纳米药物递释系统研究进展[J]. 基础医学与临床, 2022, 42(1): 2-14.
[8]	刘健. 基因治疗中的核酸药物及非病毒递送载体的研究进展[J]. 基础医学与临床, 2022, 42(1): 41-50.
[9]	李晓静, 王丽, 赵春华, 柳仁民, 马胜军, 李光耀, 任少达. 从药学视角探讨间充质干细胞产品研发的策略与进展[J]. 基础医学与临床, 2021, 41(9): 1338-1341.
[10]	钱子冰, 刘静, 曾佩芸, 张琦. mTOR调控自噬参与糖尿病并发症的研究进展[J]. 基础医学与临床, 2021, 41(8): 1200-1204.
[11]	赵艳秋, 梁伟, 洪玉娥. 老年患者阿司匹林抵抗发生率及其相关危险因素分析[J]. 基础医学与临床, 2021, 41(7): 1035-1038.
[12]	李肖肖, 边立立, 董玉明, 李娟, 刘丹丹. 月坛社区高血压患者用药及血压控制情况调查[J]. 基础医学与临床, 2021, 41(1): 93-96.
[13]	冯涛, 李晶, 潘金强, 郑殿宇, 陈辉, 杜曼·巴戈达提, 耿中利. 炎性细胞因子和凋亡相关蛋白参与大鼠下肢深静脉血栓形成[J]. 基础医学与临床, 2021, 41(1): 50-54.
[14]	刘佳奕, 章正祥, 严民力, 戚观树, 陈强, 侯群. 急性缺血性卒中患者血栓成分和影像学表现的研究进展[J]. 基础医学与临床, 2021, 41(1): 112-115.
[15]	叶阿里, 邹雨桐, 张海燕, 吴洁, 张睿, 张晓峰, 马庆伟. MALDI-TOF-MS和RT-qPCR对于SLCO1B1和ApoE多态性检测的比较[J]. 基础医学与临床, 2020, 40(7): 980-985.